Condition: Stomach Cancer Stage IV · Esophagus Cancer · Stomach Cancer · Sponsor: Massachusetts General Hospital
This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
This description comes directly from the study's public registry record.
Samuel Klempner, MD · 617-724-4000 · sklempner@mgb.org
Always discuss trial participation with your own doctor first.
| UCLA | Santa Monica, California, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07070466